Dialyzers Market Report 2025

The dialyzers market size has grown strongly in recent years. It will grow from $2.24 billion in 2024 to $2.36 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to aging population, improved healthcare infrastructure, rise in research and development, increase in number of dialysis centers.

The dialyzers market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing prevalence of chronic kidney diseases, rising disposable income, rising healthcare expenditure, growing demand for home dialysis treatment. Major trends in the forecast period include wearable dialysis devices, artificial intelligence (ai) integration, remote monitoring, value-based care models, bioengineered dialyzers.

The rising incidence of end-stage renal disease is anticipated to drive the growth of the dialyzer market in the near future. End-stage renal failure (ESRF), also known as end-stage renal disease (ESRD), represents the final, irreversible stage of chronic kidney disease, during which kidney function has declined to a level that the kidneys can no longer function independently. A dialyzer is utilized in the dialysis process to remove waste and excess fluid from the bloodstream, subsequently reinfusing the filtered blood back into the body of patients with end-stage renal disease. For example, in June 2024, the National Kidney Foundation, an organization based in India focused on combating preventable kidney disease, reported that nearly 35.5 million people in the US were diagnosed with chronic kidney disease by 2023, accounting for 33 percent of adults, or more than one in three. Additionally, while Black/African American individuals make up 13% of the U.S. population, they represent 30% of all kidney failure cases. Kidney patients receive about one-fourth of all Medicare expenditures, amounting to $156.7 billion and increasing. Thus, the rising incidence of end-stage renal disease is fueling the growth of the dialyzer market.

The rising rates of diabetes and cardiovascular disease are poised to propel the dialyzer market's growth. Diabetes and cardiovascular disease pose significant health risks, with elevated blood sugar levels contributing to an increased likelihood of heart-related conditions. Patients afflicted with diabetes and cardiovascular disease utilize dialyzers to eliminate waste products and excess fluids from their bloodstream, managing complications and enhancing overall health by addressing potential kidney dysfunction and impaired filtration. According to the World Health Organization, chronic diseases account for 74% of global fatalities, with 41 million deaths annually, encompassing 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. The mounting rates of diabetes and cardiovascular disease underscore the driving force behind the dialyzer market's expansion.

Major companies in the dialyzer market are concentrating on developing innovative products, such as hemocompatible dialyzers, to ensure reliable patient care. A hemocompatible dialyzer is specifically designed to reduce the activation of the blood's clotting system and the inflammatory response, thereby lowering the risk of complications during dialysis, including blood clots, bleeding, and infections. For example, in February 2024, Fresenius Medical Care AG & Co. KGaA, a German manufacturer of dialyzers, introduced the 5008X Hemodialysis System. This system and its accompanying FX CorAL dialyzer demonstrate the company's global leadership in innovation within medical device and membrane engineering technologies. The 5008X Hemodialysis System integrates advanced device engineering with membrane technologies to facilitate high-volume hemodiafiltration.

Major companies in the dialyzer market are pursuing a strategic partnership approach to enhance the quality of life and overall patient care experience for individuals with end-stage renal disease (ESRD). Strategic partnerships involve companies utilizing each other’s strengths and resources to achieve mutual benefits and success. For example, in September 2023, Alio Inc., a US-based medtech company, collaborated with Lifeline Vascular Care, a US-based medical firm, to introduce a new feature for its SmartPatch remote monitoring platform. This feature alerts clinicians to unusual acoustic data from a patient's vascular access site. The goal of this partnership is to improve patient management, particularly for those with end-stage kidney disease (ESKD), by enabling proactive monitoring without the necessity for frequent in-person visits.

In another strategic move, B. Braun SE, a prominent Germany-based manufacturer of dialyzers, executed an acquisition in March 2022 by acquiring Intermedt Medizin & Technik GmbH for an undisclosed amount. This strategic acquisition positions B. Braun to fortify and expand its product portfolio by gaining access to the comprehensive range of dialysis products and services offered by Intermedt. As a Germany-based manufacturer specializing in dialyzers and dialysis concentrates, Intermedt Medizin & Technik GmbH becomes an integral component of B. Braun's strategic growth and development in the dialyzer market. Through such strategic initiatives, major companies in the dialyzer market are not only enhancing their product offerings but also leveraging collaborations and acquisitions to shape the future landscape of patient care in the realm of end-stage renal disease.

Major companies operating in the dialyzers market include Medtronic PLC, Asahi Kasei Medical Co Ltd., Toray Medical Co Ltd., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Nikkiso Co Ltd., Weigao group, Fresenius Medical Care AG & Co KGaA, Allmed Medical Products Co Ltd., NxStage Medical Inc., Jiangxi Sanxin Medical Technology Co Ltd., Rockwell Medical Inc., Xenios AG., Kawasumi Laboratories Incorporated., Dialife SA, Anhui Jinye Industrial Co Ltd., Haidylena, and Farmasol S.A.

A dialyzer is a medical device utilized for filtering waste chemicals and eliminating excess fluid from an individual's blood in cases where the kidneys are not functioning properly. It acts as a substitute for the kidneys by employing semipermeable membranes to separate compounds in solution through uneven diffusion. This process effectively filters pollutants from the bloodstream of patients with kidney malfunction.

The primary types of dialyzers are high-flux dialyzers and low-flux dialyzers. High-flux dialyzers feature larger holes, allowing them to remove larger molecules such as beta-2 microglobulin. These dialyzers can be categorized based on their usage as disposable or reusable and can be employed in various settings, including in-center dialysis, home dialysis, hospital dialysis, independent dialysis, peritoneal dialysis, and home hemodialysis.

The dialyzers market research report is one of a series of new reports that provides dialyzers market statistics, including dialyzers industry global market size, regional shares, competitors with a dialyzers market share, detailed dialyzers market segments, market trends and opportunities, and any further data you may need to thrive in the dialyzers industry. This dialyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the dialyzers market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Dialyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The dialyzer market consists of revenues earned by entities by providing services such as removal of excess fluid, filtering blood from waste products. The market value includes the value of related goods sold by the service provider or included within the service offering. The dialyzer market also consists of sales of tube-type dialyzers, flat-type dialyzers, and hollow fiber-type dialyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.